Gastric Scirrhous Carcinoma

• Gastric Scirrhous Carcinoma is an aggressive and rare form of stomach cancer known for its diffuse infiltration and desmoplastic reaction.
• Unlike typical gastric cancers, it causes thickening and rigidity of the stomach wall, often leading to a “linitis plastica” appearance.
• Symptoms are often non-specific and appear late, making early diagnosis challenging.
• Diagnosis typically involves endoscopy with deep biopsies and advanced imaging techniques.
• Treatment often combines surgery with chemotherapy, but the Gastric Scirrhous Carcinoma prognosis is generally poor due to its advanced stage at diagnosis and aggressive biology.

What is Gastric Scirrhous Carcinoma?

Gastric Scirrhous Carcinoma is a highly malignant form of stomach cancer, distinct from other gastric adenocarcinomas due to its unique growth pattern. It is characterized by diffuse infiltration of poorly differentiated cancer cells into the stomach wall, accompanied by a significant desmoplastic reaction—an excessive growth of fibrous connective tissue. This reaction leads to a thickening and rigidity of the stomach wall, often referred to as “linitis plastica” or “leather bottle stomach,” which impairs the stomach’s ability to distend and contract normally.

Unlike more common forms of gastric cancer that form distinct masses or ulcers, scirrhous carcinoma spreads stealthily within the submucosal and muscular layers, making it difficult to detect early via standard endoscopic biopsies. Its aggressive biological behavior and tendency for early metastasis contribute to its challenging nature and generally unfavorable outcomes. While specific global incidence rates for scirrhous carcinoma alone are not widely reported by major health organizations, gastric cancer overall is a significant global health concern, with the World Health Organization (WHO) noting it as one of the leading causes of cancer-related deaths worldwide.

Symptoms and Diagnosis of Gastric Scirrhous Carcinoma

The Gastric Scirrhous Carcinoma symptoms are often vague and non-specific in the early stages, contributing to delayed diagnosis. As the disease progresses, symptoms become more pronounced due to the rigid, non-distensible stomach wall and potential obstruction. Common symptoms may include:

• Persistent indigestion or heartburn
• Early satiety (feeling full after eating only a small amount)
• Abdominal pain or discomfort
• Unexplained weight loss
• Nausea and vomiting, especially after meals
• Dysphagia (difficulty swallowing) if the tumor involves the cardia or gastroesophageal junction

Diagnosing Gastric Scirrhous Carcinoma can be challenging. Standard endoscopy with superficial biopsies may miss the tumor cells because they are deeply embedded within the stomach wall. Therefore, multiple deep biopsies or even surgical biopsies might be necessary. Imaging techniques play a crucial role. Computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are used to assess the extent of wall thickening, detect lymph node involvement, and identify distant metastases. Endoscopic ultrasound (EUS) can also provide detailed images of the stomach wall layers and regional lymph nodes, aiding in staging.

Treatment and Prognosis of Gastric Scirrhous Carcinoma

The Gastric Scirrhous Carcinoma treatment approach is typically multimodal, combining surgery with systemic therapies. Surgery, often a total gastrectomy (removal of the entire stomach), is the primary curative option, but its feasibility depends on the extent of the disease and whether it can be completely resected. Due to the diffuse nature of the cancer, achieving clear surgical margins can be particularly difficult. Chemotherapy, either before surgery (neoadjuvant) or after surgery (adjuvant), is commonly used to shrink tumors, eliminate residual cancer cells, and manage metastatic disease. Targeted therapy and immunotherapy may also be considered for eligible patients, depending on specific molecular markers found in the tumor.

The Gastric Scirrhous Carcinoma prognosis is generally considered poor compared to other types of gastric cancer, primarily due to its aggressive biology, late presentation, and high propensity for metastasis. Many patients are diagnosed at an advanced stage, limiting curative treatment options. Factors influencing prognosis include the stage of the cancer at diagnosis, the presence of lymph node or distant metastasis, the completeness of surgical resection, and the patient’s overall health and response to treatment. While advancements in chemotherapy and targeted therapies offer some hope, early detection remains critical for improving outcomes, though it is often difficult to achieve with this specific subtype.